Other antineoplastics molecular target inhibitors as Dasatinib (DScore 0.933), which inhibits STAT5B signalling [33], Bosutinib (DScore 0.921), Ponatinib (DScore 0.976) and Nilotinib (DScore 0.927) tyrosine-kinase inhibitors designed for the treatment of BCR_ABL positive neoplasms, mainly in chronic myeloid leukaemia but also acute lymphoblastic leukaemia, have also off-target effects on other tyrosine-kinases. Here, STAT5B is linked to chronic myelogenous leukemia, BCR-ABL1 positive.